newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

EIKN
  • Eikon Therapeutics presented updated data for EIK1001 at the 2026 ESMO Congress in Madrid, Spain.
  • EIK1001 is a TLR7/8 dual-agonist evaluated in combination with pembrolizumab & chemotherapy for first-line stage 4 non-small cell lung cancer (NSCLC).
  • TeLuRide-005 trial results showed a 72.4% objective response rate (ORR) & 100% disease control rate (DCR) in the squamous NSCLC cohort with a 12.9-month median duration of response.
  • Overall pooled data demonstrated a 63.1% ORR & 89.2% DCR across 65 efficacy-evaluable participants with a median follow-up of 17.2 months.
  • The combination therapy exhibited a tolerability profile supporting outpatient systemic administration with no Grade 3 or higher cytokine release syndrome events.
  • Grade 3 or higher treatment-related adverse events occurred in 48.6% of participants, with neutropenia being the most common.
  • No treatment-related adverse events led to death, & only 6.9% of participants discontinued treatment due to adverse events.
  • The ongoing TeLuRide-008 Phase 2/3 trial is actively enrolling participants for dose selection via an interim analysis anticipated in the second half of 2027.
  • EIK1001 dosing in the trial included once-weekly intravenous administration for 8 cycles, followed by once-every-third-week dosing.
  • Eikon plans to continue evaluating the EIK1001 combination for advanced NSCLC patients with high unmet medical needs.